Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial
Status: Enrolling
Updated:  10/15/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial
Status: Enrolling
Updated: 10/15/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated:  10/15/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated: 10/15/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated:  10/15/2015
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated: 10/15/2015
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated:  10/15/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated: 10/15/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII
Status: Enrolling
Updated:  10/15/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII
Status: Enrolling
Updated: 10/15/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII
Status: Enrolling
Updated:  10/15/2015
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII
Status: Enrolling
Updated: 10/15/2015
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Childrens National Medical Center
mi
from
Washington,
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
National Cancer Institute Pediatric Oncology Branch
mi
from
Bethesda, MD
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
National Cancer Institute Pediatric Oncology Branch
mi
from
Bethesda, MD
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Baylor College of Medicine
mi
from
Houston, TX
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated:  10/21/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 10/21/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors
Status: Enrolling
Updated:  10/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors
Status: Enrolling
Updated: 10/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma
Status: Enrolling
Updated:  10/29/2015
University of California, San Diego
mi
from
San Diego, CA
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma
Status: Enrolling
Updated: 10/29/2015
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma
Status: Enrolling
Updated:  10/29/2015
Duke Children's Hospital and Health Center
mi
from
Durham, NC
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma
Status: Enrolling
Updated: 10/29/2015
Duke Children's Hospital and Health Center
mi
from
Durham, NC
Click here to add this to my saved trials
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma
Status: Enrolling
Updated:  10/29/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma
Status: Enrolling
Updated: 10/29/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  10/30/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 10/30/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  10/30/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 10/30/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Memantine for Recurrent Glioblastoma
A Phase II Study of Memantine in the Treatment of Recurrent Glioblastoma
Status: Enrolling
Updated:  11/6/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Memantine for Recurrent Glioblastoma
A Phase II Study of Memantine in the Treatment of Recurrent Glioblastoma
Status: Enrolling
Updated: 11/6/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Preoperative Chemoradiation for Glioblastoma
Phase I Pilot Study of Preoperative Chemoradiation for Glioblastoma
Status: Enrolling
Updated:  11/7/2015
Tampa General Hospital
mi
from
Tampa, FL
Preoperative Chemoradiation for Glioblastoma
Phase I Pilot Study of Preoperative Chemoradiation for Glioblastoma
Status: Enrolling
Updated: 11/7/2015
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme
Status: Enrolling
Updated:  11/7/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme
Status: Enrolling
Updated: 11/7/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme
Status: Enrolling
Updated:  11/7/2015
University of California at San Francisco
mi
from
San Francisco, CA
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme
Status: Enrolling
Updated: 11/7/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme
Status: Enrolling
Updated:  11/7/2015
The Brain Tumor Center at Duke, Duke University Medical Center
mi
from
Box 3624 DUMC, Trent Drive, Durham, NC
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme
Status: Enrolling
Updated: 11/7/2015
The Brain Tumor Center at Duke, Duke University Medical Center
mi
from
Box 3624 DUMC, Trent Drive, Durham, NC
Click here to add this to my saved trials
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme
Status: Enrolling
Updated:  11/7/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme
Status: Enrolling
Updated: 11/7/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  11/13/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 11/13/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  11/13/2015
University of California at Los Angeles - UCLA
mi
from
Los Angeles, CA
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 11/13/2015
University of California at Los Angeles - UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  11/13/2015
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 11/13/2015
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  11/13/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 11/13/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
Comprehensive Cancer Institute of Huntsville
mi
from
Huntsville, AL
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
Comprehensive Cancer Institute of Huntsville
mi
from
Huntsville, AL
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
Huntsville Hospital System
mi
from
Huntsville, AL
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
Huntsville Hospital System
mi
from
Huntsville, AL
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
Alabama Oncology, LLC
mi
from
Montgomery, AL
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
Alabama Oncology, LLC
mi
from
Montgomery, AL
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
DCH Cancer Treatment Center
mi
from
Tuscaloosa, AL
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
DCH Cancer Treatment Center
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
Mount Diablo Medical Center
mi
from
Concord, CA
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
Mount Diablo Medical Center
mi
from
Concord, CA
Click here to add this to my saved trials
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  11/14/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 11/14/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials